Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
Han Na Jang (Jang HN), Ye Seul Yang (Yang YS), Seong Ok Lee (Lee SO), Tae Jung Oh (Oh TJ), Bo Kyung Koo (Koo BK), Hye Seung Jung (Jung HS)
Endocrinol Metab. 2019;34(4):382-389.   Published online 2019 Dec 23     DOI: https://doi.org/10.3803/EnM.2019.34.4.382
Citations to this article as recorded by Crossref logo
Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)
Han Na Jang, Hye Seung Jung
Endocrinology and Metabolism.2020; 35(1): 194.     CrossRef
Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)
Sang Youl Rhee
Endocrinology and Metabolism.2020; 35(1): 192.     CrossRef
Fear of hypoglycemia in adults with diabetes mellitus switching to treatment with IDegAsp co-formulation to examine real-world setting: an observational study (The HATICE study)
Ulaş Serkan Topaloğlu, Hatice Kayış Topaloğlu, Melih Kızıltepe, Mesut Kılıç, Sami Bahçebaşı, Sibel Ata, Şeyma Yıldız, Yasin Şimşek
Drug Metabolism and Personalized Therapy.2020;[Epub]     CrossRef